1. Home
  2. ANL

as 05-24-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Founded: 2004 Country:
Cayman Islands
Cayman Islands
Employees: N/A City: N/A
Market Cap: 387.5M IPO Year: 2023
Target Price: $30.00 AVG Volume (30 days): 8.0K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -7.26 EPS Growth: N/A
52 Week Low/High: $7.11 - $19.30 Next Earning Date: 06-04-2024
Revenue: $5,000,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: